They demonstrated that the efficacy of bispecific human IL2‐CCR4 immunotoxin in mouse cutaneous T-cell lymphoma (CTCL) was more effective than when used alone64. The gene discussed is CCR4; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.